What Pharma Can Do About Brexit: Views From The C-Suite

London-based pharma consultancy Novasecta systematically researched the implications of the Brexit vote over the three-month period since the UK referendum vote in late June. The firm shares insights from its conversations with pharma company execs, and offers advice on managing in these uncertain times.

SC1606_PencilErasingEU

The business uncertainty that was created by the UK’s referendum vote on June 23, 2016, will be felt for many years to come. The result of the vote was certainly an unwelcome surprise to the pharmaceutical industry. Novasecta privately interviewed 20 top executives from leading European pharmaceutical companies to ask how they are dealing with it. (See sidebar, "Novasecta’s Survey.") Their perspectives do not make cheerful reading for the industry. With the exception of short-term currency gains for some, the executives did not cite any clear benefits for their companies. And though most firms are watching and waiting, those that are at a point of considering new or increased long-term investment in their European R&D or manufacturing footprint are less enamored by the UK now that its relationship with the EU has become so uncertain.

Pharmaceuticals is a long-term business. The executives we interviewed were therefore universally reluctant to make immediate decisions to reverse any prior commitments that were made to the UK when it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By 

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.